Announced Sat, 8 Aug · 17:29 IST
Q1 FY27 results: Revenue up 20% YoY, PAT jumps 41.6% to Rs 4.71 cr
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.8%1-day move
₹98.21
prior close
₹107.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-1.2—-1.5+1.8+5.5+1.1+4.6+1.5+2.8————
Up moveDown movePending
AI summary
Par Drugs Q1 FY27 revenue from operations rose about 20% YoY to Rs 31.28 cr from Rs 26.05 cr. Total income was Rs 32.22 cr. PAT surged 41.6% to Rs 4.71 cr versus Rs 3.33 cr YoY. EBITDA margin improved to around 22.7% from 19.4%. EPS stood at Rs 3.83. Board also approved forward booking banking facilities from ICICI Bank, appointed NEO Alternative Asset Managers as Portfolio Manager, and purchase of vehicles for directors.
Likely market impact
Strong Q1 with double-digit revenue and PAT growth, margin expansion signals healthy operating performance. Portfolio manager appointment noted.